The global microbiome sequencing services market is poised to reach USD 1,424.7 Million by 2021 from USD 538.0 Million in 2016, at a CAGR of 21.5% from 2016 to 2021.
Key Growth Drivers:
1 Increased Focus on Human Microbiome Therapy
2 Human Microbiome as New Validated Target for Drug Development
3 Human Microbiome for Early Disease Detection and Diagnosis
2 Human Microbiome as New Validated Target for Drug Development
3 Human Microbiome for Early Disease Detection and Diagnosis
Geographic Analysis:
North America is expected to have the highest CAGR in the global microbiome sequencing services in 2016. Factors such as favorable business environment, government support through funds for genomics research, continuous developments in sequencing technologies, availability of commercial solutions for NGS data analysis, growing number of research studies on cancer & inherited rare diseases drive the growth of the market in this region.
Comments
Post a Comment